ghrelin and glp 1 Glucagon-Like Peptide-1: A Gut-Brain Axis Battle for Food Reward Schematic depiction of the roles
Description
Nat Rev Immunol
S.XanthakisV
Thus, clinical trials are needed to establish the benefits/risk profile in HF, considering that no properly designed, HF-specific randomised clinical trials have been completed with GLP-1 RAs in any of the HF phenotypes
Endocrine Today
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
